Novartis AG/Fr. NOVN
1D1W1MYTD1Y5YMAX
Capital at risk
About Novartis AG
Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel, Switzerland. It operates primarily in the healthcare industry, focusing on the research, development, and manufacturing of a wide range of prescription medications targeting oncology, immunology, neuroscience, and cardiovascular diseases. Key products include Cosentyx (for psoriasis and arthritis) and Entresto (for heart failure). Founded in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis has a significant geographic presence, with operations in over 100 countries. A key competitive strength of the company is its strong investment in research and development, which underpins its substantial portfolio of innovative therapies.
- Ticker
- Fr. NOVN
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 75,267
- Headquarters
- Basel, Switzerland
- Website
- www.novartis.com
Novartis AG Metrics
BasicAdvanced
CHF 213B
20.75
CHF 5.40
0.49
CHF 3.70
3.30%
Price and volume
Market cap
CHF 213B
Beta
0.49
52-week high
CHF 132.68
52-week low
CHF 96.03
Average daily volume
2.6M
Dividend rate
CHF 3.70
Financial strength
Current ratio
0.862
Quick ratio
0.55
Long term debt to equity
93.339
Total debt to equity
116.85
Dividend payout ratio (TTM)
71.08%
Interest coverage (TTM)
13.36%
Profitability
EBITDA (TTM)
18,861.827
Gross margin (TTM)
74.98%
Net profit margin (TTM)
22.50%
Operating margin (TTM)
32.75%
Effective tax rate (TTM)
17.88%
Revenue per employee (TTM)
CHF 612,450
Management effectiveness
Return on assets (TTM)
10.25%
Return on equity (TTM)
30.35%
Valuation
Price to earnings (TTM)
20.753
Price to revenue (TTM)
4.632
Price to book
5.13
Price to tangible book (TTM)
-7.8
Price to free cash flow (TTM)
17.34
Free cash flow yield (TTM)
5.77%
Free cash flow per share (TTM)
6.465
Dividend yield (TTM)
3.30%
Forward dividend yield
3.30%
Growth
Revenue change (TTM)
2.73%
Earnings per share change (TTM)
-3.43%
3-year revenue growth (CAGR)
8.37%
10-year revenue growth (CAGR)
1.32%
3-year earnings per share growth (CAGR)
22.59%
10-year earnings per share growth (CAGR)
8.97%
3-year dividend per share growth (CAGR)
10.48%
10-year dividend per share growth (CAGR)
5.64%
Bulls say / Bears say
Novartis delivered Q2 2026 core operating profit of $5.94 billion, surpassing the Visible Alpha consensus of $5.31 billion, driven by one-off benefits and disciplined cost control (Reuters).
The oncology and immunology portfolio powered continued momentum, with Kisqali sales up 44 percent, Scemblix up 89 percent and Cosentyx up 12 percent in Q2 2026 (Reuters).
Late-stage data readouts for pelacarsen, remibrutinib and del-desiran anticipated later in 2026 could unlock a combined peak annual sales opportunity of about $10 billion (Reuters).
Novartis forecasts its 2026 operating profit will slip by a low single-digit percentage as key drug patents expire, marking its first annual profit decline in a decade (Reuters).
Sales of Entresto, Novartis’s top heart failure therapy, plunged 50 percent in Q2 2026 due to mounting generic competition in its largest market (Reuters).
The imminent loss of exclusivity for blockbuster drugs such as Entresto and Xolair, which together represented roughly 14 percent of 2025 net sales, intensifies the company’s patent cliff challenges (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
Upcoming events
No upcoming events
Funds containing Novartis AG
AllEURGBPUSD
Fund name | Fund size | Fr. NOVN weighting |
|---|---|---|
iShares MSCI Europe Health Care Sector€ESIH | €863M | 15.44% |
iShares MSCI Europe Health Care Sector£ESIH | £741M | 15.44% |
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 14.31% |
iShares STOXX Europe 50€EXW3 | €141M | 5.69% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 5.29% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.